DHT blockers for women's hair loss are an increasingly discussed treatment option, yet navigating the evidence, licensing, and safety considerations can be complex. Dihydrotestosterone (DHT) drives follicular miniaturisation in female pattern hair loss (FPHL), but not all women are suitable candidates for anti-androgenic therapy. This article explains how DHT contributes to hair loss in women, which blockers are available in the UK, what the evidence shows, how to access treatment through the NHS or privately, and what side effects to be aware of — helping you have an informed conversation with your GP or dermatologist.
Summary: DHT blockers for women's hair loss include spironolactone, off-label finasteride, and topical formulations, used to slow or halt female pattern hair loss by reducing DHT activity on hair follicles.
- DHT causes follicular miniaturisation in genetically susceptible women, leading to female pattern hair loss (FPHL), even when circulating androgen levels are normal.
- Spironolactone is the most commonly used DHT blocker for women in the UK, prescribed off-label; finasteride and dutasteride are not licensed for women and are contraindicated in pregnancy.
- Topical minoxidil remains the only MHRA-licensed treatment specifically for female pattern hair loss and is considered first-line therapy.
- DHT blockers typically slow or halt hair loss rather than fully restore it; treatment effects may take 6–12 months to become apparent and hair loss often returns on stopping.
- Spironolactone requires monitoring of potassium and renal function; finasteride and dutasteride carry MHRA-flagged risks of psychiatric and sexual adverse effects.
- Women of childbearing age must use effective contraception when taking spironolactone, finasteride, or dutasteride, and should only access these treatments via a qualified prescriber.
Table of Contents
- How DHT Contributes to Hair Loss in Women
- Types of DHT Blockers Available in the UK
- Effectiveness and Evidence for Women's Hair Loss Treatment
- How to Access DHT Blockers Through the NHS or Privately
- Possible Side Effects and Safety Considerations for Women
- Other Treatments to Use Alongside DHT Blockers
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
How DHT Contributes to Hair Loss in Women
DHT binds to androgen receptors in hair follicles, causing progressive follicular miniaturisation that underlies female pattern hair loss, even in women with normal circulating androgen levels.
Not sure if this is normal? Chat with one of our pharmacists →
Dihydrotestosterone (DHT) is an androgen — a hormone derived from testosterone through the action of an enzyme called 5-alpha reductase. Although DHT is more commonly associated with male physiology, women also produce it in smaller quantities via the ovaries, adrenal glands, and peripheral tissues. In genetically susceptible individuals, DHT binds to androgen receptors in hair follicles, causing a process known as follicular miniaturisation. Over time, affected follicles shrink, producing progressively finer and shorter hairs until growth ceases altogether.
In women, this process underlies a condition called female pattern hair loss (FPHL), also referred to as androgenetic alopecia. It typically presents as diffuse thinning across the crown and top of the scalp, graded clinically using the Ludwig or Sinclair scales. Importantly, many women with FPHL have entirely normal circulating androgen levels — the condition is multifactorial, and follicular sensitivity to DHT varies considerably between individuals. DHT-blocking treatments will not be appropriate for everyone.
Certain conditions can raise androgen levels in women and accelerate DHT-related hair loss. These include:
-
Polycystic ovary syndrome (PCOS) — one of the most common hormonal disorders in women of reproductive age
-
Congenital adrenal hyperplasia
-
Androgen-secreting tumours (rare)
-
Menopause, during which oestrogen levels fall, altering the androgen-to-oestrogen ratio
Features of hyperandrogenism — such as hirsutism, severe acne, or irregular menstrual cycles — should prompt endocrine evaluation. Certain features warrant urgent or expedited assessment and should not be attributed to FPHL without further investigation:
-
Rapid or sudden onset of hair loss
-
Patchy hair loss, scalp pain, inflammation, or scarring (which may indicate alopecia areata or a scarring alopecia)
-
Signs of virilisation — rapidly progressive hirsutism, deepening of the voice, or clitoromegaly — which may suggest an androgen-secreting tumour
-
Broken hairs or scalp changes suggesting traction alopecia or tinea capitis
Other common causes of diffuse hair loss in women — including telogen effluvium, iron deficiency, thyroid dysfunction, and traction alopecia — should be considered and excluded before attributing hair loss to FPHL. A thorough clinical assessment by a GP or GMC-registered dermatologist is always recommended before starting any treatment. (NICE CKS: Alopecia; BAD patient information: Female pattern hair loss; NHS: Hair loss)
| Treatment | Type / Mechanism | Licensed for Women (UK) | Typical Dose (Off-label) | Key Evidence | Main Risks / Contraindications | Access |
|---|---|---|---|---|---|---|
| Topical minoxidil | Vasodilator; prolongs anagen phase | Yes — first-line for FPHL | 2% or 5% solution/foam, once or twice daily | Strongest evidence base for women; NICE-endorsed first-line | Scalp irritation; unwanted facial hair; avoid in pregnancy | NHS & over the counter |
| Spironolactone (oral) | Androgen receptor blocker; modest adrenal androgen suppression | No — off-label for FPHL | 50–200 mg daily under specialist supervision | 2020 JAAD study: meaningful regrowth/stabilisation in significant proportion of women; best evidence among DHT blockers for women | Hyperkalaemia, menstrual irregularities, breast tenderness; contraindicated in pregnancy; effective contraception required | NHS (specialist) or private prescription |
| Finasteride (oral) | 5-alpha reductase inhibitor (type II); reduces DHT production | No — MHRA-licensed for men only | 2.5–5 mg daily in post-menopausal women only, under specialist supervision | 1 mg daily ineffective in RCTs for post-menopausal women; higher doses used off-label | Absolutely contraindicated in pregnancy/breastfeeding; psychiatric and sexual side effects; MHRA safety guidance applies | Private specialist prescription only |
| Dutasteride (oral) | 5-alpha reductase inhibitor (type I & II); more potent than finasteride | No — not licensed for women | Consult SmPC | Limited trial data in women; more potent DHT suppression than finasteride | Same contraindications as finasteride; absolutely contraindicated in pregnancy | Private specialist prescription only |
| Topical finasteride / spironolactone | Localised 5-alpha reductase inhibition or androgen receptor blockade | No — unlicensed in UK | Consult SmPC; via regulated private prescriber | Early data suggest localised benefit with reduced systemic effects; large RCTs in women lacking | Systemic absorption possible; finasteride formulations contraindicated in pregnancy and breastfeeding | CQC-registered private prescribers only |
| Saw palmetto / pumpkin seed oil | Natural 5-alpha reductase inhibitors (proposed mechanism) | N/A — supplements, not medicines | No established dose for FPHL | Very limited clinical evidence; not endorsed by NICE or NHS for FPHL | Variable quality; high-dose zinc can cause copper deficiency; discuss with clinician before use | Over the counter |
Types of DHT Blockers Available in the UK
Spironolactone, finasteride, and dutasteride are the main DHT blockers used in the UK for women, all prescribed off-label; finasteride and dutasteride are absolutely contraindicated in pregnancy.
DHT blockers work by either inhibiting the 5-alpha reductase enzyme (thereby reducing DHT production) or by blocking androgen receptors so that DHT cannot exert its effects on hair follicles. Several options are available in the UK, though their licensing and suitability for women varies considerably.
Finasteride is a 5-alpha reductase inhibitor licensed in the UK for benign prostatic hyperplasia and male pattern baldness. It is not licensed for use in women by the MHRA, and is absolutely contraindicated in women who are pregnant, trying to conceive, or breastfeeding due to the risk of feminisation of a male foetus. Even handling crushed or broken tablets poses a risk through dermal absorption. It is sometimes prescribed off-label to post-menopausal women under specialist supervision, but only at doses above 1 mg (see Effectiveness section). Women prescribed finasteride should be counselled about psychiatric and sexual side effects in line with current MHRA safety guidance (see Side Effects section).
Experiencing these side effects? Our pharmacists can help you navigate them →
Dutasteride inhibits both type I and type II 5-alpha reductase enzymes, making it more potent than finasteride. Like finasteride, it is not licensed for women and carries the same contraindications in those who are or may become pregnant.
Spironolactone is an aldosterone antagonist whose primary anti-androgenic action is blockade of androgen receptors, with some modest suppression of adrenal androgen synthesis. Although not licensed specifically for hair loss, it is widely used off-label in the UK for FPHL — particularly in women with evidence of hyperandrogenism — and is available only on prescription. It is contraindicated in pregnancy, and effective contraception is required for women of childbearing age.
Some topical formulations containing low-dose finasteride or spironolactone are available through private clinics and regulated online prescribers. It is important to note that these products are unlicensed in the UK. Topical finasteride can still be absorbed systemically and therefore remains contraindicated in pregnancy and breastfeeding, and should not be used by women who are trying to conceive.
Certain over-the-counter supplements — such as saw palmetto, pumpkin seed oil, and zinc — are marketed as natural DHT blockers. The clinical evidence supporting their use in FPHL is very limited, and they are not endorsed by NICE or the NHS for this purpose. Supplement quality is variable, and some carry risks: high-dose zinc supplementation, for example, can cause copper deficiency. Women should discuss supplement use with their clinician before starting, particularly if taking other medicines. (MHRA/EMC SmPCs: Finasteride, Dutasteride; BNF: Spironolactone; MHRA Drug Safety Update: Cyproterone acetate and meningioma risk)
Effectiveness and Evidence for Women's Hair Loss Treatment
Spironolactone has the strongest evidence in women, particularly those with elevated androgens or PCOS; finasteride at 1 mg daily has not demonstrated efficacy in post-menopausal women in high-quality trials.
The evidence base for DHT blockers in women's hair loss is growing, though it remains less robust than for male pattern baldness. Most clinical trials have historically focused on male populations, leaving a relative gap in high-quality data for women.
Topical minoxidil is the only medicine licensed in the UK specifically for female pattern hair loss and is considered first-line treatment. DHT blockers are used off-label and are typically considered as adjuncts or alternatives when minoxidil alone is insufficient or not tolerated.
Spironolactone has the most evidence in women. A 2020 retrospective study published in the Journal of the American Academy of Dermatology found that spironolactone produced meaningful hair regrowth or stabilisation in a significant proportion of women with FPHL. It appears particularly effective in women with elevated androgens or PCOS-related hair loss, though some benefit has also been observed in those with normal androgen levels. Doses used off-label typically range from 50–200 mg daily under specialist supervision; women of childbearing potential must use effective contraception throughout treatment.
Finasteride at 1 mg daily has not demonstrated efficacy in post-menopausal women with FPHL in high-quality randomised controlled trials. Where it is used off-label in post-menopausal women, it is at higher doses (typically 2.5–5 mg daily) under specialist supervision, with appropriate counselling about risks. It is not considered a first-line option for women.
Topical DHT blockers are an area of active research. Early data on topical finasteride and spironolactone solutions suggest they may offer localised benefit with reduced systemic side effects compared with oral formulations, though large-scale randomised controlled trials in women are still lacking, and these products remain unlicensed in the UK.
It is important to set realistic expectations:
-
DHT blockers are more likely to slow or halt progression than to fully restore lost hair
-
Treatment effects may take 6–12 months to become apparent
-
Hair loss often returns if treatment is discontinued
-
Response varies significantly between individuals
Women considering these treatments should discuss the available evidence with a GP or GMC-registered dermatologist to make an informed decision. (NICE CKS: Alopecia; PCDS: Female pattern hair loss guidance; systematic reviews on spironolactone in FPHL)
How to Access DHT Blockers Through the NHS or Privately
NHS access begins with a GP consultation and targeted investigations; referral to dermatology or endocrinology may be needed, and private CQC-registered prescribers offer an alternative route.
Accessing DHT blockers for hair loss in women through the NHS can be challenging, as treatments such as spironolactone and finasteride are not licensed for this indication. NHS prescribing of unlicensed or off-label medicines is subject to individual clinical judgement and local commissioning policies, meaning availability may vary across different regions of England, Scotland, Wales, and Northern Ireland.
The typical NHS pathway begins with a GP consultation, during which the pattern, severity, and likely cause of hair loss will be assessed. Investigations should be guided by clinical findings rather than requested routinely for all women. In line with NICE CKS guidance, the following are commonly considered:
-
Full blood count (to exclude anaemia)
-
Thyroid function tests
-
Serum ferritin (iron stores)
-
Androgen profile — including total testosterone, SHBG, and DHEAS — only if there are signs of hyperandrogenism (e.g., hirsutism, irregular menses, severe acne)
-
Prolactin and 17-hydroxyprogesterone where clinically indicated (e.g., suspected hyperprolactinaemia or congenital adrenal hyperplasia)
If an underlying condition such as PCOS or thyroid disease is identified, treating that condition may itself improve hair loss. Referral should be considered in the following circumstances:
-
Dermatology — for diagnostic uncertainty, suspected scarring alopecia, or hair loss that is not responding to initial treatment; expedited or urgent referral for suspected scarring alopecia
-
Endocrinology or gynaecology — for significant hyperandrogenism or suspected PCOS
-
Urgent assessment — if virilisation or an androgen-secreting tumour is suspected
For faster access, many women choose to consult privately with a GMC-registered dermatologist. Regulated online prescribing services registered with the Care Quality Commission (CQC) can assess suitability and prescribe treatments such as spironolactone or topical formulations. Costs vary, but private consultations typically range from £100–£250, with ongoing prescription costs on top.
It is important to note that trichologists are not medically qualified and cannot prescribe medicines. Whilst they may offer useful advice on hair and scalp health, diagnosis and prescribing decisions should be made by a GP or GMC-registered specialist.
Women should ensure any online prescriber is CQC-registered and that prescriptions are issued following a proper clinical assessment — not simply on the basis of a questionnaire alone. (NICE CKS: Alopecia, Hirsutism, PCOS; PCDS: Primary care pathway for FPHL)
Possible Side Effects and Safety Considerations for Women
Spironolactone can cause menstrual irregularities and hyperkalaemia; finasteride and dutasteride carry MHRA-flagged risks of depression, suicidal thoughts, and sexual dysfunction, and are contraindicated in pregnancy.
As with all prescription medicines, DHT blockers carry a risk of side effects, and safety considerations are particularly important for women given the hormonal nature of these treatments.
Spironolactone is generally well tolerated but can cause:
-
Menstrual irregularities — including spotting or changes in cycle length, particularly at higher doses
-
Breast tenderness or enlargement
-
Hyperkalaemia (elevated potassium levels) — particularly in women with renal impairment or those taking ACE inhibitors, angiotensin receptor blockers (ARBs), NSAIDs, or potassium supplements
-
Dizziness or low blood pressure, particularly on standing
-
Increased urinary frequency due to its diuretic properties
-
Fatigue or headaches
Potassium and renal function (U&Es) should be checked at baseline and after dose changes; ongoing monitoring should be tailored to individual risk, including renal function, age, and interacting medicines. Spironolactone is contraindicated in pregnancy, and effective contraception is required for women of childbearing age. Key interactions include ACE inhibitors, ARBs, and potassium-sparing agents, which increase the risk of hyperkalaemia.
Finasteride and dutasteride are absolutely contraindicated in women who are pregnant, trying to conceive, or breastfeeding — including topical formulations, which can be absorbed systemically. Even handling crushed or broken tablets poses a risk through dermal absorption.
In line with the MHRA 2024 Drug Safety Update, women prescribed finasteride (or dutasteride) off-label should be counselled about the risk of psychiatric and sexual adverse effects, including:
-
Depression and low mood
-
Suicidal thoughts — women should be advised to stop the medicine immediately and seek urgent medical help if these occur
-
Reduced libido and sexual dysfunction
These effects have been reported to persist in some individuals after stopping treatment.
Topical formulations generally carry a lower risk of systemic side effects, though local skin reactions such as irritation or dryness may occur. The pregnancy contraindication still applies.
Women should contact their GP or prescriber promptly if they experience:
-
Significant menstrual changes
-
Symptoms of high potassium (muscle weakness, palpitations, irregular heartbeat)
-
Mood changes, depression, or thoughts of self-harm
-
Any signs of an allergic reaction
Suspected side effects from any medicine can be reported to the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk — this helps improve medicine safety for everyone.
Self-prescribing or purchasing DHT blockers without medical supervision is strongly discouraged, as appropriate assessment and monitoring are essential for safe use. (MHRA Drug Safety Update 2024: Finasteride — psychiatric and sexual adverse reactions; BNF: Spironolactone interactions and monitoring; MHRA/EMC SmPCs: Finasteride, Dutasteride)
Other Treatments to Use Alongside DHT Blockers
Topical minoxidil is the licensed first-line treatment for FPHL and is commonly combined with DHT blockers; correcting nutritional deficiencies and addressing psychological wellbeing are also important components of care.
DHT blockers are rarely used in isolation. A comprehensive approach to female hair loss typically combines hormonal or anti-androgenic treatments with other evidence-based interventions to maximise results and address multiple contributing factors.
Minoxidil is the only topical treatment licensed in the UK specifically for female pattern hair loss and is considered first-line therapy. Regaine for Women 5% w/w cutaneous foam (minoxidil) is licensed and available to purchase directly from UK pharmacies without a prescription. The 2% solution is less commonly used. Minoxidil works by prolonging the anagen (growth) phase of the hair cycle and improving follicular blood supply. It is often used alongside spironolactone or other DHT blockers for a complementary effect. Results typically require consistent daily use for at least four to six months.
Low-dose oral minoxidil is also used in some specialist settings for FPHL, though it is unlicensed for this indication and should only be initiated and monitored by a specialist due to potential cardiovascular side effects (including fluid retention and tachycardia).
Nutritional optimisation plays a supportive role. Deficiencies in the following have been associated with hair shedding and should be corrected where identified:
-
Iron and ferritin — low stores are a common and treatable cause of diffuse hair loss in women
-
Vitamin D
-
Zinc — note that supplementation should only be considered if deficiency is confirmed; high-dose zinc can cause copper deficiency
-
Biotin — deficiency is rare in those eating a balanced diet; high-dose biotin supplements can interfere with certain laboratory assays (including thyroid function tests and troponin), potentially causing misleading results. The MHRA has issued guidance on this risk; biotin supplementation should be avoided unless deficiency is confirmed
Low-level laser therapy (LLLT), delivered via UKCA/CE-marked devices such as laser combs or helmets, has some emerging evidence for stimulating hair growth and may complement medical treatments. However, it is not routinely recommended or commissioned by the NHS for FPHL.
Platelet-rich plasma (PRP) therapy, available privately, involves injecting concentrated growth factors from the patient's own blood into the scalp. Evidence is promising but not yet sufficient for NHS adoption, and it is not routinely commissioned.
Finally, addressing psychological wellbeing is an important and often overlooked aspect of hair loss management. Hair loss can significantly affect self-esteem and mental health; referral to a counsellor or support organisations such as Alopecia UK may be beneficial alongside medical treatment. A holistic, patient-centred approach consistently yields the best long-term outcomes. (EMC SmPC: Regaine for Women 5% w/w cutaneous foam; NHS: Minoxidil; MHRA guidance: Biotin interference with laboratory tests; NICE CKS: Alopecia)
Frequently Asked Questions
Can women actually take DHT blockers for hair loss, or are they only for men?
Women can use certain DHT blockers for hair loss, but the options differ from those used in men. Spironolactone is the most widely prescribed option for women in the UK, used off-label; finasteride and dutasteride are not licensed for women and are contraindicated in pregnancy, though finasteride is sometimes prescribed off-label to post-menopausal women under specialist supervision.
How long does it take for a DHT blocker to work for women's hair loss?
DHT blockers typically take 6–12 months before any meaningful effect on hair loss becomes apparent in women. Treatment is more likely to slow or halt progression than to fully restore lost hair, and results vary considerably between individuals.
Is spironolactone safe to take long-term for female hair loss?
Spironolactone is generally well tolerated for long-term use in women, but it requires regular monitoring of potassium levels and kidney function, particularly in those with renal impairment or taking interacting medicines such as ACE inhibitors. Women of childbearing age must use effective contraception throughout treatment, as it is contraindicated in pregnancy.
What is the difference between finasteride and spironolactone for women's hair loss?
Finasteride reduces DHT production by inhibiting the 5-alpha reductase enzyme, whereas spironolactone primarily blocks androgen receptors and has some effect on adrenal androgen synthesis. Spironolactone has more supporting evidence in women and is more commonly prescribed off-label in the UK; finasteride is generally reserved for post-menopausal women under specialist supervision and carries stricter contraindications.
Do natural DHT blockers like saw palmetto actually work for women's hair loss?
The clinical evidence for natural DHT blockers such as saw palmetto or pumpkin seed oil in female pattern hair loss is very limited, and they are not endorsed by NICE or the NHS for this purpose. Supplement quality is variable and some carry risks — high-dose zinc, for example, can cause copper deficiency — so women should discuss any supplements with their clinician before starting.
What should I do if I think I need a DHT blocker for my hair loss but my GP won't prescribe one?
If your GP is unable to prescribe a DHT blocker, ask for a referral to a NHS dermatologist or, if there are signs of hormonal imbalance, to endocrinology or gynaecology. Alternatively, a private consultation with a GMC-registered dermatologist or a CQC-registered online prescriber can assess your suitability and prescribe treatments such as spironolactone following a proper clinical assessment.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
